Puriya W. Yazdanfard
Herlev, Denmark
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications
Accounting for non-adherence: A re-analysis of the Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results trial.
Journal: Clinical trials (London, England)
Published: June 02, 2026
Timing and duration of glucagon-like peptide-1 receptor agonist use and risk of nonarteritic anterior ischaemic optic neuropathy.
Journal: Acta ophthalmologica
Published: January 31, 2026
Consumer Food Purchases After Glucagon-Like Peptide-1 Receptor Agonist Initiation.
Journal: JAMA network open
Published: January 26, 2026
Sustained glucagon-like peptide-1 receptor agonist treatment improves glycemic control and reduces all-cause mortality compared to dipeptidyl peptidase-4 inhibitors: A real-world target trial emulation in type 2 diabetes.
Journal: Diabetes, obesity & metabolism
Published: November 07, 2025
Type 2 diabetes, sodium-glucose cotransporter-2 inhibitors and cardiovascular outcomes: real world evidence versus a randomised clinical trial.
Journal: Cardiovascular diabetology
Published: June 20, 2025
Real-world cardiovascular effectiveness of sustained glucagon-like peptide 1 GLP-1 receptor agonist usage in type 2 diabetes.
Journal: Cardiovascular diabetology
Published: April 28, 2025
Association between socioeconomic factors and semaglutide use for weight loss: a population-based cross-sectional study in Denmark.
Journal: The Lancet regional health. Europe
Published: April 25, 2025
Hearing loss in fabry disease: A 16 year follow-up study of the Danish nationwide cohort.
Journal: Molecular genetics and metabolism reports
Published: November 22, 2021
Showing 1-11 of 11
Last Updated: 09/26/2026